Diabetes and HIV: Current understanding and future perspectives

Current Diabetes Reports

Volumn 13, Issue 3, 2013, Pages 419-427

  Kalra, Sanjay ^a   Agrawal, Navneet ^b  

^a Bharti Hospital ^*  (India)

^b Diabetes Obesity and Thyroid Centre   (India)

Author keywords

Diabetes; Glucose; HIV; Insulin; Insulin resistance; Lipids; Lipodystrophy; Metabolic syndrome; Metformin; Obesity

Indexed keywords

ABACAVIR; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; C PEPTIDE; CANAGLIFLOZIN; DARUNAVIR; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN; GLUCOSE TRANSPORTER 4; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; INSULIN; INSULIN ASPART; INTERLEUKIN 10; LEPTIN; METFORMIN; NEVIRAPINE; ORAL ANTIDIABETIC AGENT; PROTEINASE INHIBITOR; RECOMBINANT GROWTH HORMONE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; AGE DETERMINATION; AGE DISTRIBUTION; ALBUMINURIA; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME INHIBITION; ETHNICITY; EXERCISE; FAINTNESS; GENDER BIAS; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KETONURIA; KIDNEY INJURY; LACTIC ACIDOSIS; LIPODYSTROPHY; MITOCHONDRIAL TOXICITY; MIXED INFECTION; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR; SCREENING; SIDE EFFECT; WASTING SYNDROME; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HIV INFECTIONS; MASS SCREENING; PUBLIC HEALTH;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HIV INFECTIONS; HUMANS; MASS SCREENING; PUBLIC HEALTH;

EID: 84877747085     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0369-9     Document Type: Review

References (74)

1. Global Report. UNAIDS Report on the Global AIDS Epidemic. 2010. Available at: http://www.unaids.org/globalreport/documents/20101123-GlobalReport-full-en. pdf. The report gives the latest statistics for HIV worldwide.
2. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-9. (Pubitemid 29278477)
3. Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, et al. HIV infection and the risk of diabetes mellitus. AIDS. 2009;23:1227-34.
4. Calza L, Masetti G, Piergentili B, Trapani F, Cascavilla A, Manfredi R, et al. Prevalence of diabetes mellitus, hyperinsulinaemia, and metabolic syndrome among 755 adult patients with HIV-1 infection. Int J STD AIDS. 2011;22:43-5. A longer exposure to antiretroviral therapy and a diagnosis of lipodystrophy syndrome were significantly associated with both metabolic disturbances.
5. Galli L, Salpietro S, Pellicciotta G, Galliani A, Piatti P, Hasson H, et al. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol. 2012;27(8):657-65
6. Hadigan C. Diabetes, insulin resistance, and HIV. Curr Infect Dis Rep. 2006;8:69-75. (Pubitemid 43154244)
7. Florescu D, Kotler DP. Insulin resistance, glucose intolerance, and diabetes mellitus in HIV-infected patients. Antivir Ther. 2007;12:149-62. (Pubitemid 46569900)
8. Samaras K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep. 2012;9:206-17. A recent review about current evidence base and clinical guidelines for diabetes and lipid management and cardiometabolic prevention in HIV-infected HAART recipients.
9. Salehian B, Bilas J, Bazargan M, Abbasian M. Prevalence and incidence of diabetes in HIV-infected minority patients on protease inhibitors. J Natl Med Assoc. 2005;97:1088-92. (Pubitemid 41102233)
10. Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res. 2006;4:79-85.
11. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-30.
12. Das S. Insulin resistance and diabetes in HIV infection. Recent Pat Antiinfect Drug Discov. 2011;6:260-8. The present review article has the information of patients regarding the insulin resistance in HIV infection.
13. Krishnan S, Shouten JT, Atkinson B, Brown T, Wohl T, McComsey GA, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr. 2012;61(3):381-9
14. Abdel-Khalek I, Moallem HJ, Fikrig S, Castells S. New onset diabetes mellitus in an HIV-positive adolescent. AIDS Patient Care STDS. 1998;12:167-9. (Pubitemid 28150905)
15. Kalra S KB, Agrawal N, Unnikrishnan A. Understanding diabetes in patients with HIV/AIDS. Diabetol Metab Syndr. 2011;3(1):2
16. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298-302. (Pubitemid 36331702)
17. Brar I, Shuter J, Thomas A, Daniels E, Absalon J. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral-naive individuals vs individuals in the national health and nutritional examination survey cohort. J Acquir Immune Defic Syndr. 2007;45:66-71. (Pubitemid 46684444)
18. Kourtis AP, Bansil P, Kahn HS, Posner SF, Jamieson DJ. Diabetes trends in hospitalized HIV-infected persons in the United States, 1994-2004. Curr HIV Res. 2009;7:481-6.
19. Brambilla AM, Novati R, Calori G, Meneghini E, Vacchini D, Luzi L, et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS. 2003;17:1993-5. (Pubitemid 37070289)
20. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010;33:2244-9.
21. Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology. 2004;40:115-9. (Pubitemid 38868929)
22. Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV cohort study. Clin Infect Dis. 2007;45:111-9. (Pubitemid 46984626)
23. Howard AA, Hoover DR, Anastos K, Wu X, Shi Q, Strickler HD, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's interagency HIV study. J Acquir Immune Defic Syndr. 2010;54:152-9.
24. Monroe A. HIV/AIDS and diabetes: minimizing risk, optimizing care. BETA. 2009;21:38-44.
25. Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 2012;26:303-14.
26. Gonzalez-Tome MI, Ramos Amador JT, Guillen S, Solis I, Fernandez-Ibieta M, Munoz E, et al. Gestational diabetes mellitus in a cohort of HIV-1 infected women. HIV Med. 2008;9:868-74.
27. Gianotti N, Visco F, Galli L, Barda B, Piatti P, Salpietro S, et al. Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients. HIV Med. 2011;12:109-17.
28. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31:1224-9.
29. Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's interagency HIV study. AIDS. 2007;21:1739-45. (Pubitemid 47237561)
30. Srivanich N, Ngarmukos C, Sungkanuparph S. Prevalence of, and risk factors for pre-diabetes in HIV-1-infected patients in Bangkok, Thailand. J Int Assoc Physicians AIDS Care. 2010;9:358-61.
31. Revuelta MP. Cumulative insults to mitochondrial function may promote the emergence of 'syndrome X' and diabetes mellitus in HIV/HCV co-infected patients. Mitochondrion. 2004;4:175-84. (Pubitemid 39549807)
32. Jain MK, Aragaki C, Fischbach L, Gibson S, Arora R, May L, et al. Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. HIV Med. 2007;8:491-7. (Pubitemid 47616827)
33. Lo YC, Chang SY, Sheng WH, Hung CC, Chang SC. Association of pancreatic autoantibodies and human leukocyte antigen haplotypes with resolution of diabetes mellitus after therapy for hepatitis C virus infection in patients with HIV infection: case report and review of literature. Eur J Gastroenterol Hepatol. 2009;21:478-81.
34. Hamill M, Brook G. An association between HIV/HCV co-infection and diabetes mellitus-is there a need for routine blood glucose monitoring? J Clin Virol. 2005;33:176-8. (Pubitemid 40725313)
35. Rotger M, Gsponer T, Martinez R, Taffe P, Elzi L, Vernazza P, et al. Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. Clin Infect Dis. 2010;51:1090-8.
36. Holly JM, Amiel SA, Sandhu RR, Rees LH, Wass JA. The role of growth hormone in diabetes mellitus. J Endocrinol. 1988;118:353-64.
37. Smith JC, Evans LM, Wilkinson I, Goodfellow J, Cockcroft JR, Scanlon MF, et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol. 2002;56:493-501. (Pubitemid 34429624)
38. Schauster AC, Geletko SM, Mikolich DJ. Diabetes mellitus associated with recombinant human growth hormone for HIV wasting syndrome. Pharmacotherapy. 2000;20:1129-34.
39. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr. 1999;21:209-16. (Pubitemid 29331215)
40. Trabattoni D, Schenal M, Cesari M, Castelletti E, Pacei M, Goldberg B, et al. Low interleukin-10 production is associated with diabetes in HIV-infected patients undergoing antiviral therapy. Med Microbiol Immunol. 2006;195:125-32. (Pubitemid 44421172)
41. Takarabe D, Rokukawa Y, Takahashi Y, Goto A, Takaichi M, Okamoto M, et al. Autoimmune diabetes in HIV-infected patients on highly active antiretroviral therapy. J Clin Endocrinol Metab. 2010;95:4056-60.
42. Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, et al. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet. 2010;86:88-92.
43. Kalra SUA, Raza SA, Bantwal G, Baruah MP, Latt TS, Shrestha D, et al. South Asian consensus guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. Indian J Endocr Metab. 2011;15:242-50. The recent South Asian Guidelines about diagnosis and management of diabetes in HIV patients.
44. Hresko RC, Hruz PW. HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4. PLoS One. 2011;6:e25237.
45. Deloumeaux J, Maachi M, Sow-Goerger MT, Lamaury I, Velayoudom FL, Cheret A, et al. Adiponectin and leptin in afro-Caribbean men and women with HIV infection: association with insulin resistance and type 2 diabetes. Diabetes Metab. 2011;37:98-104.
46. Idiculla J, Ravindra'n GD, D'Souza J, Singh G, Furruqh S. Diabetes mellitus, insulin resistance, and metabolic syndrome in HIV-positive patients in south India. Int J Gen Med. 2011;4:73-8.
47. Garg H, Joshi A, Mukherjee D. Cardiovascular complications of HIV infection and treatment. Cardiovasc Hematol Agents Med Chem. 2012 Aug 30 Accessed 15 Sept 2012
48. Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (D:A:D study). Circulation. 2009;119:805-11.
49. Calza L. Renal toxicity associated with antiretroviral therapy. HIV Clin Trials. 2012;13:189-211.
50. Cohen DB, Allain TJ, Glover S, Chimbayo D, Dzamalala H, Hofland HW, et al. A survey of the management, control, and complications of diabetes mellitus in patients attending a diabetes clinic in Blantyre, Malawi, an area of high HIV prevalence. AmJTrop Med Hyg. 2010;83:575-81.
51. Medapalli RK, Parikh CR, Gordon K, Brown ST, Butt AA, Gibert CL, et al. Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the veterans aging cohort study. J Acquir Immune Defic Syndr. 2012;60:393-9.
52. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. Racial differences in end-stage renal disease rates in HIV infection vs diabetes. J Am Soc Nephrol. 2007;18:2968-74. (Pubitemid 350058405)
53. Kim PS, Woods C, Dutcher L, Georgoff P, Rosenberg A, Mican JA, et al. Increased prevalence of albuminuria in HIV-infected adults with diabetes. PLoS One. 2011;6:e24610.
54. Kim PS, Woods C, Georgoff P, Crum D, Rosenberg A, Smith M, et al. A1C underestimates glycemia in HIV infection. Diabetes Care. 2009;32:1591-3.
55. Eckhardt BJ, Holzman RS, Kwan CK, Baghdadi J, Aberg JA. Glycated hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals. AIDS Patient Care STDS. 2012;26:197-201.
56. Tien PC, Schneider MF, Cox C, Karim R, Cohen M, Sharma A, et al. Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr. 2012;61(3):334-40.
57. Beatty GKM, Abbasi F, Chu J, Reaven GM, Rosen A, et al. Quantification of insulin-mediated glucose-disposal in HIV-infected individual: comparision of patients treated and untreated with protease inhibitors. J Acquir Immune Defic Syndr. 2003;33:34-40. (Pubitemid 36547239)
58. Fairchild AL, Alkon A. Back to the future? diabetes, HIV, and the boundaries of public health. J Health Polit Policy Law. 2007;32:561-93. (Pubitemid 47293828)
59. American Diabetes Association (ADA) Clinical Practice Recommendations. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care. 2012;35:S11-63. Recent ADA guidelines about medical care in diabetes with focus on patient centric approach.
60. Polo R, Jose Galindo M, Martinez E, Alvarez J, Arevalo JM, Asensi V. et al [recommendations of the study group for metabolic alterations/secretariat for the national AIDS plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection]. Enferm Infecc Microbiol Clin. 2006;24:96-117.
61. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000;284:472-7. (Pubitemid 30484481)
62. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab. 2002;87:4611-5. (Pubitemid 35247049)
63. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
64. Aberg JAKJ, Libman H, Emmanuel P, Anderson JR, Stone VE, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651-81.
65. Kalra S, Unnikrishnan AG, Raza SA, Bantwal G, Baruah MP, Latt TS, et al. South Asian consensus guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. Indian J Endocrinol Metab. 2011;15:242-50.
66. Kalra SKB, Nanda G. OPD management of ketosis in pregnancy: aspart vs regular insulin. Diabet Med. 2006;23:504.
67. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
68. Grinspoon S. Diabetes mellitus, cardiovascular risk, and HIV disease. Circulation. 2009;119:770-2.
69. Dube MPSD, Henry WK, Aberg JA, Torriani FJ, Hodis HN, Schouten J, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the adult AIDS clinical trial group cardiovascular disease focus group. Clin Infect Dis. 2000;31:1216-24. (Pubitemid 32295453)
70. Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, et al. A randomized, open-label comparison of 3 highly active antiretroviral therapy regimens including 2 nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS. 2000;14:1171-80. (Pubitemid 30420660)
71. Janssens B, Van Damme W, Raleigh B, Gupta J, Khem S, Soy Ty K, et al. Offering integrated care for HIV/AIDS, diabetes and hypertension within chronic disease clinics in Cambodia. Bull World Health Organ. 2007;85:880-5. (Pubitemid 350086461)
72. Tzoupis H, Leonis G, Megariotis G, Supuran CT, Mavromoustakos T, Papadopoulos MG. Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations. J Med Chem. 2012;55:5784-96.
73. Questions and answers on the review aliskiren-containing medicines: European Medicines Agency. 2012.
74. Pandey K, Sinha PK, Rabidas V, Kumar N, Bimal S, Verma N, et al. HIV, visceral leishmaniasis, and Parkinsonism combined with diabetes mellitus and hyperuricaemia: a case report. Cases J. 2008;1:183.